D dimer News and Research

RSS

ARDS may not be the primary lung iInjury in COVID-19

A new Italian study published on the preprint server medRxiv in August 2020 shows that this may not be an adequate explanation, since ARDS is a nonspecific diagnosis. Instead, they say, antemortem lung biopsy shows a “Covid pattern” of acute lung injury, which could guide the application of therapeutics.

16 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

Five biomarkers in blood linked to higher odds of clinical deterioration, death in COVID-19 patients

George Washington University researchers found five biomarkers, medical indicators found in the blood, associated with higher odds of clinical deterioration and death in COVID-19 patients.

6 Aug 2020

Research explains recognized sex differences in COVID-19 outcomes

The COVID-19 pandemic has notably taken a more significant toll on men compared to women, in terms of both disease severity and death. Now, a new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in August 2020 confirms the increased risk that males have for death following COVID-19 while also highlighting worse outcomes in women with coronary artery disease, obesity, and hypoxia compared to men.

3 Aug 2020

New simple way of detecting COVID-19 in blood plasma

Even as the COVID-19 pandemic claims increasing numbers of patients, testing numbers are rising in most nations at the leading edge. However, the current reverse transcriptase-polymerase chain reaction (RT PCR) testing is often unavailable and takes up to several days for results to arrive.

31 Jul 2020

Platelet hyperreactivity, a unique feature of COVID-19

A new study by Irish researchers and published in the preprint server medRxiv in July 2020 reports a bidirectional relationship between COVID-19 and coagulation abnormalities.

29 Jul 2020

Researchers identify anticoagulation agent that suppresses SARS-CoV-2 replication in vitro

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction.

27 Jul 2020

Prednisone, Hydroxychloroquine best among COVID-19 treatments, claims large Spanish study

The COVID-19 pandemic has taken the lives of several hundred thousand people across the world. In Spain, a intense outbreak took a toll of over 28,000 lives.

23 Jul 2020

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

22 Jul 2020

New guideline can help clinicians identify hard-to-diagnose acute aortic syndrome

A new guideline aimed at helping clinicians identify the difficult-to-diagnose acute aortic syndrome is published in CMAJ (Canadian Medical Association Journal).

20 Jul 2020

Clots, COVID-19 and survival

The novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes COVID-19 disease, was first reported in Wuhan, Hubei Province of China in late December 2019. Since then, it has infected a large population across the world with the current number of SARS-CoV-2 infections standing at over 13 million and COVID-19 disease having killed over 571,000 individuals.

13 Jul 2020

Study: Cellular therapy can improve critical cases of COVID-19

A cellular therapy tested on 13 intubated patients with mechanical ventilation has shown to be efficient for the clinical improvement of critical cases of COVID-19.

8 Jul 2020

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.

7 Jul 2020

Latest findings put Benson Viscometers at the forefront of Covid-19 fight

A clinical viscosity diagnostic instrument is proving to be valuable in the research and treatment of coronavirus after laboratory scientists have identified its ability to provide meaningful data for medical teams treating Covid-19 patients.

3 Jul 2020

Markers of vascular damage in COVID-19

A new study by researchers at Yale University and published on the preprint server medRxiv reports on the plasma levels of biomolecules that reflect vascular damage in COVID-19.

2 Jul 2020

HORIBA Medical white paper provides a review of hematology biomarkers for COVID-19 assessment

As experts in hematology HORIBA UK Ltd, Medical announces that the Company has published a white paper entitled, ‘COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients’.

From HORIBA Medical 26 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Researchers find prothrombotic antibodies in patients with COVID-19

Even as the COVID-19 pandemic continues to spread across the world, researchers are still trying to understand the many ways in which it can manifest and its pathogenesis. A new report published on the preprint server medRxiv* in June 2020 shows that one possible mechanism of disease in COVID-19 is the production of antiphospholipid antibodies.

19 Jun 2020

Deep vein thrombosis common in patients with moderate to severe COVID-19

In their paper available on the medRxiv preprint server, researchers from Russia showed that patients with moderate and severe coronavirus disease (COVID-19) have a high incidence of deep vein thrombosis – indicating that they may necessitate an early administration of anticoagulation therapy as a part of their treatment regimen.

15 Jun 2020

Tocilizumab in Critical COVID-19 Patients

A new study by scientists at Metro Infectious Disease Consultants and published on the preprint server medRxiv* in June 2020 reports that the cytokine blocker tocilizumab is a useful adjunct to supportive medical care in severe COVID-19, with increased survival and a lower requirement for mechanical ventilation.

10 Jun 2020